Pharming nominates CFO
This article was originally published in Scrip
The board of supervisory directors at Pharming (the Netherlands) has nominated Dr Karl Keegan for appointment as chief financial officer and member of the board of management. The company will hold an extraordinary general meeting of shareholders on 1 October to request approval for Dr Keegan's appointment as a board member. Dr Keegan was most recently CFO of Minster Pharmaceuticals, a drug development company which was acquired by Proximagen Neuroscience in February. Before that, he worked at Canaccord Adams as managing director, UK head of equity research and global head of life sciences research and as a biotechnology analyst at several investment banks, including Banc of America, UBS and Dresdner Kleinwort Benson.